REFERENCES

Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T. 2001. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine 134(8):663–694.


CDC (Centers for Disease Control and Prevention). 2002a. Protocol 1: AVA human reactogenicity and immunogenicity trial to address change in route of administration and dose reduction. Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.

CDC. 2002b. Protocol 2: Non-human primate vaccine dose ranging, immunogenicity and challenge trial (Battelle Memorial Institute). Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.

CDC. 2002c. Protocol 3: Correlates of protection study (Emory University). Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.

CDC. 2002d. Protocol 4: Correlates of protection study (Battelle Memorial Institute). Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.

CDC. 2002e. Section 1: anthrax vaccine safety and efficacy plan. Anthrax Vaccine Safety and Efficacy Plan.Atlanta: Centers for Disease Control and Prevention..

CDC. 2002f. Section 3: critical research questions table. Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.

CDC. 2002g. Section 5: CDC responses to specific IOM questions. Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.

CDC. 2002h. Section 6: Study summary: AVA human reactogenicity and immunogenicity trial to address change in route of administration and dose reduction. Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.

CDC. 2002i. Section 7: Study summary: non-human primate (NHP) vaccine dose ranging, immunogenicity and challenge trial. Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.

CDC. 2002j. Section 8: Study summary: immune correlates of protection against inhalation anthrax—part C of the anthrax vaccine research program. Anthrax Vaccine Safety and Efficacy Plan. Atlanta: Centers for Disease Control and Prevention.


Hayney MS, Poland GA, Jacobson RM, Rabe D, Schaid DJ, Jacobsen SJ, Lipsky JJ. 1998. Relationship of HLADQA1 alleles and humoral antibody following measles vaccination. International Journal of Infectious Diseases 2(3):143–146.

Hayney MS, Poland GA, Jacobson RM, Schaid DJ, Lipsky JJ. 1996. The influence of the HLA-DRB1*13 allele on measles vaccine response. Journal of Investigative Medicine 44(5):261–263.

Health Technology Assessment News. 1999. Intent-to-treat principle misunderstood despite journal editors’ adoption of standards. September–October. Plymouth Meeting, Pa.: ECRI.


IOM (Institute of Medicine). 2001. CDC Anthrax Vaccine Safety & Efficacy Research Program.Interim Report. Washington, D.C.: National Academy Press.

IOM. 2002. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, eds. The Anthrax Vaccine: Is It Safe? Does It Work? Washington, D.C.: National Academy Press.

Ivins BE, Ezzell JW Jr, Jemski J, Hedlund KW, Ristroph JD, Leppla SH. 1986. Immunization studies with attenuated strains of Bacillus anthracis. Infection and Immunity 52(2):454–458.

Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. 1992. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infection and Immunity 60(2):662–668.

Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GW Jr, Gibbs PH, Friedlander AM. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16(11–12):1141–1148.


Pittman PR, Hack D, Mangiafico J, Gibbs P, McKee KT Jr, Friedlander AM, Sjogren MH. 2002. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. Vaccine 20(16):2107–2115.

Poland GA, Jacobson RM, Schaid D, Moore SB, Jacobsen SJ. 1998. The association between HLA class I alleles and measles vaccine-induced antibody response: evidence of a significant association. Vaccine 16(19):1869–1871.


St. Sauver JL, Ovsyannikova IG, Jacobson RM, Jacobsen SJ, Vierkant RA, Schaid DJ, Pankratz VS, Green EM, Poland GA. 2002. Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. The Journal of Infectious Diseases 185(11):1545–1549.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement